An antibody, also known as an immunoglobulin, is used for various purposes such as enzyme-linked immunosorbant assay (ELISA), flow cytometric analysis, immunohistochemistry, immunoprecipitation, immunocytochemistry, and western blotting. It a large, Y-shaped protein used to neutralize pathogens such as pathogenic bacteria and viruses. Monoclonal antibodies (MAbs) are diagnostic reagents made by identical immune cells that are all clones of a unique parent cell. These antibodies are used in diagnosis of chlamydia, herpes simplex, HIV, hepatitis, and influenza infections and for the treatment of various types of cancer. MAbs are also used in biomedical and microbiological research.
Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2048
MAbs can be used to detect the presence of a given substance in diagnostic tests. MAbs are used as reagents in diagnostic tests of enzyme-linked immunosorbent assays and radioimmunoassay in laboratories. Measurement of the circulating concentrations of hormones (insulin, progesterone, thyroid-stimulating hormone, gastrin, growth hormone, human chorionic gonadotropin, thyroxine, triiodothyronine, and renin) and cell products (histocompatibility antigens, interferon, blood clotting factors, blood group antigens, interleukins, and tumor markers) is the major objective of these tests.
MAbs are used in diagnostic medicine during tests to determine the concentration of specific proteins in blood or urine. For instance, high blood level of a prostate-specific antigen is measured by its interaction with a monoclonal antibody for early detection of prostate cancer. MAbs can target biomarkers of carcinogenic-embryonic antigen (colorectal cancer), HER-2/neu proteins (breast cancer), prostate-specific antigen (expressed in prostate cancer), CA125 (ovarian cancer), CA15-3 antigen, and CA19-9 (gastrointestinal cancer).
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2048
Increasing adoption of MAbs to augment the market growth
MAbs are increasingly used in R&D of cancer and immunological disorders therapies, which is expected to boost growth of the global monoclonal antibody diagnostic reagents market. Moreover, MAb diagnostic kits are increasingly used to detect communicable diseases such as transfusion transmissible infections (TTI). Therefore, increasing prevalence of infectious disease is also expected to propel the market growth. For instance, according to the World Health Organization (WHO) data of 2017, 15 million deaths are registered annually due to infectious diseases in emerging economies. Tropical parasitic infections such as schitosomiasi and sexually transmitted infections such as syphilis can also be fatal. Such scenario increases the demand for stable, accurate, and simple, diagnostic tools.
Increasing prevalence of non-infectious diseases is expected to lead to high demand for their diagnosis, thereby aiding in growth of the global monoclonal antibody diagnostic reagents market over the forecast period. For instance, according to WHO 2017 data, chronic respiratory diseases, diabetes, cardiovascular diseases, stroke, and cancer lead to around 40 million deaths, annually worldwide. Moreover, according to the International Agency for Research on Cancer (IARC), the incidence of cancer is expected to reach to 26.8 million new cases and 17.1 million deaths annually by the year 2030.
MAbs have high binding accuracy to several pathogens, which makes them effective biological reagents in immunodiagnostic assays. However, production of the right antibody and its attachment to a compound is challenging, time consuming, expensive, and labor-intensive. This in turn is expected to restrict growth of the global monoclonal antibody diagnostic reagents market.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/monoclonal-antibody-diagnostic-reagents-market-2048
North America is expected to account for the largest market share
Developed healthcare infrastructure and high government funding for R&D in cancer is expected to place North America as the dominant market during the forecast period. For instance, in 2016, National Cancer Institute (NCI) received a total funding of US$ 4.952.6 billion, reflecting an increase of five percent, or US$ 262.1 million from 2015. Moreover, increasing approval and commercialization of MAbs products in the U.S. and Europe is also expected to boost the market growth in North America and Europe.
Asia Pacific is witnessing increasing prevalence of lifestyle-induced diseases and growing population. Therefore, Asia Pacific market is expected to witness the highest growth during the forecast period. For instance, according to WHO data, non-communicable diseases deaths are projected to increase by 15% between 2010 and 2020, with the highest numbers predicted in the Western Pacific (12.3 million deaths) and South-East Asia (10.4 million deaths) regions.
Monoclonal Antibody Diagnostic Reagents Market Competitive Landscape
Key players operating in the monoclonal antibody diagnostic reagents market include AnaSpec, BioGenex, Bio-Rad, Biocare Medical, BioVision, Celltrion, Creative Diagnostics, GenWay Biotech, Innovent Biologics, Medix Biochemica, Qiagen, and Teva Pharmaceutical Ltd.
Monoclonal Antibody Diagnostic Reagents Market Taxonomy
On the basis of diagnostic tests, the global monoclonal antibody diagnostic reagents market is segmented into:
- Dot-immunogold Filtration Assay
- Double Antigen Sandwich Chemiluminescence Method
- Enzyme-Linked Immunosorbent Assay
- Recombinant Immunoblot Assay
On the basis of application, the global monoclonal antibody diagnostic reagents market is segmented into:
- Hormones Diagnosis
- Tumor Monitoring
- Virus Detection
- Other Applications
On the basis of region, the global monoclonal antibody diagnostic reagents market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027